Interestingly, PD1 antibody plus chemotherapy was the most used neoadjuvant regimen in most retrospective studies related to this field [22–24], which was similar in our study, where 47.4% of CRC patients and 70.5% of GC patients received PD1 blockade combined with chemotherapy. Here, PDCD1 is linked to gastric cancer.